Personalized cancer vaccine trial halted early – what we know

NCT ID NCT06175221

Terminated Disease control Sponsor: Elios Therapeutics, LLC Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This phase 2 trial tested a personalized cancer vaccine called TLPO in 63 people with various solid tumors. The vaccine was made from a patient's own tumor material to train their immune system to fight the cancer. The study aimed to see if the vaccine could delay disease progression and improve survival, but it was terminated early, so the full results are not available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Tumor lysate particle only (TLPO) vaccine
What this could lead to: If successful, this vaccine could help the immune system recognize and attack a patient's own cancer, potentially slowing tumor growth or preventing recurrence.
What could go wrong: This was a small, early-phase trial that was terminated, so results are limited. The vaccine is personalized and complex, and it may not work for all tumor types or patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer metastatic neoplasm neoplasm Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CANCER TUMOR TUMOR METASTASIS TUMOR, SOLID

Contacts and locations

Locations

Southside Medical Center

Greenville, South Carolina, 29615, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.